PDLLA3000-mPEG2000, PDI≤1.25
Based on 1 Customer Validation
PDLLA3000-mPEG2000, PDI≤1.25 is an amphiphilic block copolymer composed of methoxy poly(ethylene glycol) and poly(D,L-lactide). PDLLA3000-mPEG2000, PDI≤1.25 functions as a self-assembled polymeric micelle component to enhance aqueous solubility and oral bioavailability in bioactive substances. PDLLA3000-mPEG2000, PDI≤1.25 can be used in the study of drug delivery.
For research use only. We do not sell to patients.
- Purity: 95.0%
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
PDLLA3000-mPEG2000, PDI≤1.25, combined with d-α-tocopherol acid of polyethylene glycol succinat (TPGs), forms a homogeneous, stable spherical micellar system with a particle size of 67.42 nm, PDI of 0.229, and zeta potential of -18.67 mV when used to fabricate Hyperoside (HY-N0452)-loaded micelles via thin film dispersion[1].
PDLLA3000-mPEG2000, PDI≤1.25 (0.1-10 μg/mL; 12 h dark incubation), combined with TPGs, forms blank micelles with a critical micelle concentration of 2.56 μg/mL, indicating excellent self-assembly capability and stability[1].
PDLLA3000-mPEG2000, PDI≤1.25 (10-200 μg/mL; 48 h), combined with TPGs, forms blank micelles that exhibit low cytotoxicity[1].
PDLLA3000-mPEG2000, PDI≤1.25 forms stable spherical nanomicelles with glucose-Paclitaxel (HY-B0015), achieving a high encapsulation efficiency of 95.59% and drug loading of 11.46%, with no significant changes in size or zeta potential over 28 days of storage at 25°C or 4°C[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human foreskin fibroblast (HFF) cells
-
Concentration:10 μg/mL; 25 μg/mL; 50 μg/mL; 100 μg/mL; 200 μg/mL
-
Incubation Time:48 h
-
Result:Maintained HFF cell viability above 80% at all tested concentrations, indicating low cytotoxicity and good biocompatibility.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 200 g)[1]
-
Dosage:2.5 mg/mL
-
Administration:i.g.; single dose
-
Result:Achieved an 8-fold increase in oral bioavailability (AUC0-t = 16.08 μg·h/mL vs. 2.07 μg·h/mL for free hyperoside).
Extended half-life by 3-fold (t1/2 = 28.70 h vs. 9.43 h for free hyperoside).
Increased maximum plasma concentration (Cmax = 1.11 μg/mL vs. 0.71 μg/mL for free hyperoside).
Delayed time to maximum concentration (Tmax = 4 h vs. 3 h for free hyperoside).
Extended mean residence time (MRT0-t = 13.23 h vs. 3.31 h for free hyperoside).
Chemical Information
-
Appearance Solid
-
Color White to off-white
-
SMILES
COCCOC(C(OC(C(C)O)=O)C)=O.[n].[m]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Xia X, et al. Hyperoside-loaded TPGs/mPEG-PDLLA self-assembled polymeric micelles: preparation, characterization and in vitro/in vivo evaluation. Pharm Dev Technol. 2022 Sep;27(7):829-841. [Content Brief]
[2]. Yan D, et al. Nanomicellar Prodrug Delivery of Glucose-Paclitaxel: A Strategy to Mitigate Paclitaxel Toxicity. Int J Nanomedicine. 2025;20:2087-2101. Published 2025 Feb 17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)